Literature DB >> 619265

Circulating immune complexes and complement activation in primary biliary cirrhosis.

J R Wands, J L Dienstag, A K Bhan, E R Feller, K J Isselbacher.   

Abstract

We evaluated 20 patients with primary biliary cirrhosis and seven controls with extrahepatic biliary obstruction for presence of circulating immune complexes, having found serologic evidence of alternate complement-pathway activation in eight of the 20. Immune complexes were isolated by cryoprecipitation from serum and measured directly by the sensitive Raji-cell radioimmunoassay. Cryoproteins, found in high concentrations in 90 per cent of the patients with cirrhosis but undetectable in the controls, were composed of IgM (60 per cent), IgG-IgM (25 per cent) and IgA-IgM (5 per cent) and were capable of activating the complement system in vitro. Immune complexes detected by the Raji assay were found in 95 per cent of the patients with cirrhosis and circulated in exceedingly high concentrations (474 microgram per milliliter; range, 16.2 to 2192) but were absent in the controls. Furthermore, the alternate complement pathway was activated in eight cirrhotic patients. These complement-fixing immune complexes differ from immune complexes isolated from other types of liver diseases and may be important in the pathogenesis of primary biliary cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 619265     DOI: 10.1056/NEJM197802022980502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  46 in total

Review 1.  Primary biliary cirrhosis: considerations on pathogenesis based on identification of the M2 autoantigens.

Authors:  I R Mackay; M E Gershwin
Journal:  Springer Semin Immunopathol       Date:  1990

2.  The ultrastructure of intrahepatic bile ducts in primary biliary cirrhosis.

Authors:  Y H Xu; Z B Wu
Journal:  J Tongji Med Univ       Date:  1986

3.  Studies on circulating soluble immune complexes of the liver disease. 1. Inhibition assay of polyclonal rheumatoid factor binding to IgG-sepharose.

Authors:  J Narumoto; T Arima; K Kunishi; T Yasuhara; K Suwaki; H Shimomura; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1979-12

4.  Suppressor cell activity in primary biliary cirrhosis.

Authors:  R K Zetterman; J A Woltjen
Journal:  Dig Dis Sci       Date:  1980-02       Impact factor: 3.199

Review 5.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

6.  D-penicillamine for primary biliary cirrhosis.

Authors:  O F James
Journal:  Gut       Date:  1985-02       Impact factor: 23.059

Review 7.  Primary biliary cirrhosis.

Authors:  D R Triger
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-26

8.  Role of plasmapheresis in primary biliary cirrhosis.

Authors:  L B Cohen; E P Ambinder; A M Wolke; S P Field; F Schaffner
Journal:  Gut       Date:  1985-03       Impact factor: 23.059

9.  Studies on the frequency and pathogenesis of liver involvement in rheumatoid arthritis.

Authors:  L Fernandes; S Sullivan; I G McFarlane; B M Wojcicka; T W Warnes; A L Eddleston; E B Hamilton; R Williams
Journal:  Ann Rheum Dis       Date:  1979-12       Impact factor: 19.103

10.  Complement activation in chronic liver disease.

Authors:  L E Munoz; D De Villiers; D Markham; K Whaley; H C Thomas
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.